 About Us
DCVCompany Summary:
- DCV Technologies, Inc. (DCV) is a private, biopharmaceutical company focusing on the development of therapeutic vaccines for reproductive tract and other cancers
- The company has rights to patented tumor marker antigens discovered at the University of Arkansas for Medical Sciences (UAMS)
- DCV’s proprietary approach combines the key areas of tumor marker discovery and dendritic cell vaccine technology for the induction of tumor-specific immune responses
- Products are personalized allowing an attack on an individual’s tumor using the patient’s own immune system
- Our technology has been approved for use in a Phase I trial for cervical cancer
- We have completed preclinical work for vaccines for prostate and ovarian cancers and are seeking FDA approval for Phase I trials of these vaccines
- Our offices and laboratories are located in the UAMS Arkansas BioVentures biotechnology incubator in Little Rock, AR
|
|
|
